Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor

References

• Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347–59
   PubMed Web of Science ®Google Scholar
• de Lannoy IAM, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551–7
   PubMed Web of Science ®Google Scholar
• Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood–brain barrier via P-glycoprotein. Drug Metab Dispos 2008;36:6–9
   PubMed Web of Science ®Google Scholar
• Challa VR, Babu PR, Challa SR, et al. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm 2013;39:865–72
   PubMed Web of Science ®Google Scholar
• Babu PR, Babu KN, Haroled PL, et al. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Dev Ind Pharm 2013;39:873–9
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001;12:361–7
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998;21:1062–6
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multi drug transporter. Ann Rev Pharmacol Toxicol 1999;39:361–98
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:S73–86
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998;56:847–69
   PubMed Web of Science ®Google Scholar
• Kamiyama E, Nakai D, Mikkaichi T, et al. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52–8
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen X, Gu Y, Liang J. Transport characteristics of candesartan in human intestinal Caco-2 cell line. Biopharm Drug Dispos 2009;30:259–64
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine 2012;8:740–7
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan cilexetil. Pharm Dev Technol 2009;14:290–8
   PubMed Web of Science ®Google Scholar
• Gurunath S, Nanjwade BK, Patil PA. Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J 2013 (in press, available online 8 April 2013)
   Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068–75
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-micro emulsifying formulation for candesartan cilexetil. AAPS PharmSciTech 2010;11:9–17
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Del Rev 2007;59:645–66
   PubMed Web of Science ®Google Scholar
• Gurunath S, Shailesh S, Patil PA, Nanjwade BK. Formulation and evaluation of fast dissolving tablets of Candesartan cilexetil by vacuum drying technique. J Pharmacy Res 2011;4:4195--8
   Google Scholar
• Patil BS, Gada MM, Kulkarni U, Rao KD. Formulation and development of candesartan cilexetil fast dissolving tablets by solid dispersion technique. Int J Drug Formul Res 2011;2:338--47
   Google Scholar
• FDA. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services, Centre for Drug Evaluation and Research (CEDER); 1997
   Google Scholar
• ICH (Q2R1). Guideline on validation of analytical procedures: text and methodology. Proceedings of the International Conference on Harmonization; 2007; Geneva
   Google Scholar
• Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Expert Rev Cardiovasc Ther 2004;2:829–35
   PubMedGoogle Scholar
• Yonemochi E, Ueno Y, Ohmae T, et al. Evaluation of amorphous ursodeoxycholic acid by thermal methods. Pharm Res 1997;14:798–803
   PubMed Web of Science ®Google Scholar
• Yonemochi E, Kitahara S, Maeda S, et al. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur J Pharm Sci 1999;7:331–8
   PubMed Web of Science ®Google Scholar
• Mura P, Cirri M, Faucci MT, et al. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal 2002;30:227–37
   PubMed Web of Science ®Google Scholar
• Dai WG, Dong LC, Song YQ. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm 2007;342:201–7
   PubMed Web of Science ®Google Scholar
• Kubo H, Mizobe M. Improvement of dissolution rate and oral bioavailability of a sparingly water-soluble drug, (+/−)-5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]-methyl]-2, 4-thiazolidinedione, in co-ground mixture with D-mannitol. Biol Pharm Bull 1997;20:460–3
   PubMed Web of Science ®Google Scholar
• Purvis T, Vaughn JM, Rogers TL, et al. Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm 2006;324:43–50
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Saito M, Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spray-drying technique. J Pharm Pharmacol 1975;27:1–5
   PubMed Web of Science ®Google Scholar
• Chow A. Assessment of wettability and its relationship to the intrinsic dissolution rate of doped phenytoin crystals. Int J Pharm 1995;126:21–8
   Web of Science ®Google Scholar
• Benet LZ, Wu CY, Hebert MF, Wacher VJ. Intestinal drug metabolism and anti-transport processes: a potential paradigm shift in oral drug delivery. J Control Release 1996;39:139–43
   Web of Science ®Google Scholar
• Benet LZ, Cummins CL. The drug efflux-metabolism alliance: bio-chemical aspects. Adv Drug Deliv Rev 2001;50:S3–11
   PubMed Web of Science ®Google Scholar
• Wacher JV, Salphati L, Benet LZ. Active secretion and enterocylic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001;46:89–102
   PubMed Web of Science ®Google Scholar